News

Results from FARETINA-DME indicate a majority of eyes with DME began extending treatment intervals after 1-2 initial doses of faricimab.

This new data from the UK suggests possible opportunities for preventing anxiety and depression for those with eczema or psoriasis by addressing modifiable risk factors such as sleep.

Joshua Neumiller, PharmD, takes part in a Q&A on the role of deprescribing in older adults with diabetes mellitus based on a presentation from the Association of Diabetes Care and Education Specialists 2023 annual meeting.

With an uptick in COVID-19 cases, it is time for a reminder of the recommendations of how rheumatoid arthritis treatment should be amended if a patient is exposed to SARS-CoV-2. Test your knowledge with this quiz.

Positive topline results from the phase 3 trial suggest once-daily OCS-01 met both primary trial endpoints for the treatment of inflammation and pain following cataract surgery.

An analysis of postmenopausal women shows a nearly two-fold increase in liver cancer incidence among those who consume at least 1 soft drink or fruit drink daily.

In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.

This study’s findings demonstrate the necessity of risk factor identification for atopic-like dermatitis, as well as the importance of exploring alternative treatments for severe cases.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.

Vistagen reported significant improvement of physician- and patient-reported anxiety among trial participants who underwent an anxiety-inducing public speaking exercise.

The new research in this study indicates that both types of food challenges may be equally useful when conducted by trained staff who use strict objective stop criteria.

Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.

While discussing a review of noninvasive options, the gastroenterologist addresses the growing interest in non-colonoscopy screening and surveillance methods.

The empagliflozin reference drug and its biosimilar (CKD-370) demonstrated bioequivalence, and both treatments were well-tolerated among patients.

Data from PK profiles and safety analyses of intravitreal sozinibercept suggest the promise of the drug in combination with standard anti-VEGF agents for AMD and DME.

Approximately 1 in 5 newly diagnosed patients are initiating direct acting antivirals within 6 months, according to Medicaid data review.

These new findings suggest the COMSA parameters may have applicability for standardizing observational studies’ results for pediatric patients with asthma.

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

The data from this analysis indicates that for those with psoriasis, effective and long-term continuous control of the skin disease could diminish risk of CCVD risk.

Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development.

The approval is the second granted to a geographic atrophy drug that targets the complement pathway.

The apparent risk increases for use of these medications over the past 2 decades suggests the global importance of health care reforms and focus on drug safety.

Clayton, a primary investigator in the drug's pivotal trials, discusses what the historic FDA approval means for managing PPD in women.

The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.

Presented at ASRS 2023, results from a posthoc analysis of YOSEMITE/RHINE suggest a potential anti-fibrotic effect of faricimab versus aflibercept in eyes with DME.

The results found those with sexual minority status were significantly more likely to attend prenatal care visits (20%) when compared with heterosexual women.

Presented at ASRS 2023, results from FARETINA-AMD suggest positive early treatment patterns and outcomes in patients with nAMD initiating faricimab treatment.